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A retrospective study was performed to assess the histopathologic findings in high-risk women undergoing bilateral prophylactic
(salpingo)-oophorectomy. The medical files of BRCA1 or BRCA2 mutation carriers and members of a hereditary breast/ovarian
cancer (HBOC) family, who had undergone prophylactic surgery, were reviewed. In all, 38 women underwent a bilateral
oophorectomy (26 BRCA1, three BRCA2 and nine HBOC, respectively). A total of 90 women underwent bilateral salpingo-
oophorectomy (58 BRCA1, six BRCA2, one BRCA1 and 2, 25 HBOC, respectively). At the time of salpingo-oophorectomy, five of
58 BRCA1 carriers (8.6%) were diagnosed with an occult carcinoma: two fallopian tube carcinomas, two ovarian carcinomas and one
case was defined as a fallopian tube/ovarian carcinoma. No occult carcinomas were found in the other groups. Of the 38 patients,
who underwent a bilateral oophorectomy (mean follow-up 45 months), three of 26 BRCA1 mutation carriers (3.4 in 100 women-
years) developed peritoneal papillary serous carcinoma (PPSC) during follow-up. So far, no PPSC have occurred in the 90 women,
who underwent a salpingo-oophorectomy (mean follow-up 12 months), including 58 BRCA1 carriers (0 in 60 in women-years).
These results contribute to the thesis that BRCA1 germline mutation carriers are not only at risk for ovarian cancer, but also for
fallopian tube carcinoma and peritoneal papillary serous carcinoma. Our data suggest that PPSC risk among BRCA2 carriers is lower
than among BRCA1 carriers.
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Women with a BRCA1 or BRCA2 germline mutation are at an
increased risk of developing breast and ovarian cancer. At the age
of 70, the cumulative risk of developing ovarian cancer in a BRCA1
mutation carrier ranges from 16 to 85%, whereas the risk with a
BRCA2 mutation is 10–27% (Ford et al, 1994, 1998; Easton et al,
1995; Burke et al, 1997; Struewing et al, 1997). Annual screening by
assessing serum CA-125 and transvaginal ultrasound monitoring is
recommended in these patients (Burke et al, 1997). Since the
efficiency of these screenings methods is still not clear (Lafram-
boise et al, 2002), prophylactic surgery of the ovaries for patients
with proven BRCA1 or BRCA2 mutations or a strong family
history of breast and/or ovarian cancer is an important option
(Eisen et al, 2000; Rebbeck et al, 2002). It has been found that this
procedure reduces the risk of ovarian cancer by 96% and breast
cancer by 53% in BRCA1 or BRCA2 mutation carriers (Kauff et al,
2002; Rebbeck et al, 2002).
Fallopian tube carcinoma comprises 0,.5% of all gynaecologic
tumours (Schneider et al, 2000). The true incidence is probably
underestimated, since most patients diagnosed with fallopian tube
carcinoma present with more advanced disease involving the tubes
as well as the ovaries and are classified as ovarian cancer. Primary
fallopian tube carcinoma can only be diagnosed when the largest
bulk of the carcinoma is present in the fallopian tube, or if a
transition of dysplastic tubal epithelium to carcinoma is observed
(Woolas et al, 1997). In cases where there is no evidence which
favours either a fallopian tube carcinoma or an ovarian carcinoma,
the term tubo-ovarian carcinoma is used (Scully et al, 2003).
Fallopian tube cancer has been reported in BRCA1 and BRCA2
germline mutation carriers recently (Schubert et al, 1997; Tong
et al, 1999; Hartley et al, 2000; Rose et al, 2000; Sobol et al, 2000;
Zweemer et al, 2000; Agoff et al, 2002).
There is a growing number of manuscripts reporting the
incident findings of tumours at prophylactic salpingo-oophor-
ectomy, including patients with fallopian tube cancer (Salazar et al,
1996; Hartley et al, 2000; Lu et al, 2000; Colgan et al, 2001; Paley
et al, 2001; Agoff et al, 2002; Kauff et al, 2002; Leeper et al, 2002;
Rebbeck et al, 2002). However, these are either small
studies including no more than 60 patients or studies without a
clear distinction between either salpingo-oophorectomy vs an
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loophorectomy, or BRCA1 vs BRCA2 carriers. The development of
peritoneal papillary serous carcinoma (PPSC) has also been
observed after prophylactic surgery of the ovaries. (Tobacman
et al, 1982; Chen et al, 1985; Lynch et al, 1986, 1991; Piver et al,
1993; Kauff et al, 2002; Rebbeck et al, 2002). No comparison has
been made between the outcome of a bilateral oophorectomy and
the outcome of a bilateral salpingo-oophorectomy.
The purpose of this study is to assess the prevalence of
histopathologic findings at bilateral prophylactic (salpingo)-
oophorectomy and incidence in follow-up based on the findings
of 128 high-risk women.
PATIENTS AND METHODS
Patients
Clinical data of women who had undergone a prophylactic
oophorectomy or salpingo-oophorectomy at the Antoni van
Leeuwenhoek Hospital were obtained from clinical charts. The
women were determined to be at high risk by the following criteria:
BRCA1 or BRCA2 germline mutation carriers or women with
breast cancer from a hereditary breast-ovarian cancer (HBOC)
family. DNA testing was either done before the prophylactic
surgery or performed after testing became available. If no mutation
was found in a person herself or in her family, the DNA result was
called non-informative. Women were seen by a gynaecologic
oncologist once a year for a gynaecologic examination, transva-
ginal ultrasound and serum CA-125 determination, also after the
prophylactic surgery for screening of papillary serous peritoneal
cancer.
From January 1990 to November 2001, we identified 38 women
(mean age 47 years) who had undergone prophylactic oophor-
ectomy, and 90 patients (mean age 46 years) who received
prophylactic salpingo-oophorectomy (Table 1). In May 1997, an
incidental salpingo-oophorectomy was performed, while the
standard procedure up till that time was a bilateral oophorectomy.
In this patient, an occult fallopian tube carcinoma was found. This
finding, together with the growing number of articles about
salpingo-oophorectomy, prompted us to extend the prophylactic
procedure from oophorectomy to salpingo-oophorectomy. In all,
35 patients underwent a primary laparotomic bilateral oophor-
ectomy, 93 a laparoscopy, from which 10 operations were
converted into a laparotomy. The mean age of all women was 46
years, range 26–74 years.
Pathology
After oophorectomy or salpingo-oophorectomy, the ovaries and
fallopian tubes were entirely sectioned. Occult carcinoma was
defined as follows: the patients were not suspected of having an
ovarian malignancy before surgery, determined by patient history,
pelvic examination, transvaginal examination or serum CA-125
determination, and the tumour was an unexpected finding seen
only at histological examination. The histological diagnosis
fallopian tube carcinoma was based on tumour size, histological
markers and histological subtype. To study the relation between
normal fallopian tube tissue and the carcinoma in a BRCA1
mutation carrier, a molecular analysis was performed in one
patient. DNA was isolated by micro dissecting areas of 10mm and
extracted in a solution of TNE buffer, 500mM EDTA and
20mgml
 1 proteinase K. The isolated DNA was analysed for
BRCA1 loss of heterozygosity (LOH) by polymerase chain reaction
using 10 microsatellite markers, six spanning chromosome 17 and
four spanning other chromosomes. P53 staining was performed in
all cases with a carcinoma, because BRCA1 germline mutation
carriers with breast cancer were more likely to be positive for p53
protein compared with sporadic breast cancer patients (Lakhani
et al, 2002). P53 expression was detected immunohistochemically
using D0–7 monoclonal antibodies (DAKO, Denmark) and scored
as overexpressed when staining was present in more than 50% of
tumour cells.
RESULTS
Characteristics of the 38 women (mean age 47 years, range 31–64)
who underwent an oophorectomy and the 90 women (mean age 46
years, range 26–74) who underwent a salpingo-oophorectomy are
depicted in Table 1. There was no difference between the two
groups in terms of percentage with BRCA1 or BRCA2 mutations or
percentage with a history of breast cancer.
In the group of women who underwent an oophorectomy, no
occult carcinomas were found. In the second group of women with
a salpingo-oophorectomy, five occult tumours were found in 8.6%
of 58 BRCA1 mutation carriers (Table 2): two cases of fallopian
tube carcinoma, one case of fallopian tube/ovarian carcinoma and
two cases of ovarian carcinoma. The patients with an occult
tumour had a mean age of 42.2 years (range 33–49). All five
tumours were only detected at microscopic pathological examina-
tion. At subsequent staging procedures, there were two FIGO stage
1A, one stage 1C, one 3B and one stage 4 carcinomas. Despite
adjuvant chemotherapy, two patients (patient 2 and 3) developed a
recurrence after 11 and 20 months.
The microscopical examination of patient 1 showed a tumour
embolus with a diameter of 2.5mm nearly completely obliterating
the lumen of the left fallopian tube (Figure 1). P53 staining was
negative. To examine the role of BRCA1 in fallopian tube
carcinoma development in this patient, DNA was isolated from
the tumour and from the surrounding normal tissue for a BRCA1
LOH analysis. Six markers were selected located in the vicinity of
the BRCA1 locus at chromosome 17. An LOH of the nonmutated
BRCA1 allele was detected in the fallopian tube tissue. The patient
is alive and well after 46 months of follow-up.
At 1 year after treatment for breast cancer with surgery,
adjuvant chemotherapy and tamoxifen, patient 2 underwent
prophylactic salpingo-oophorectomy. Only at microscopy, a
primary serous papillary adenocarcinoma (diameter 10mm) at
the end of the fallopian tube was detected. Overexpression of p53
was observed. Despite postoperative chemotherapy, a recurrence
was noted after 20 months. The pathology of patient 3 revealed a
poorly differentiated adenocarcinoma spread diffusely in both
fallopian tubes and one ovary (diameter 5mm). In the lymphatic
vessels of the fallopian tubes tumour fragments were noticed.
However, the bulk of the tumour was seen on the surface of the
ovary as well as both tubes. The diagnosis ‘fallopian tube/ovarian
carcinoma’ was made. The tumour cells were p53 positive. At 11
months after confirming the initial diagnosis, she had a
recurrence. Patient 4 was treated 3 years before for breast cancer.
At prophylactic surgery, an occult ovarian carcinoma with a
Table 1 Patient characteristics of 38 patients with a bilateral
oophorectomy and 90 patients with a bilateral salpingo-oophorectomy
Bilateral
oophorectomy
Bilateral salpingo-
oophorectomy
Characteristics N¼38 % N¼90 %
Previous breast cancer 28 74 55 61
Laparoscopic surgery 24 63 59 66
Laparotomic surgery 14 37 31 34
BRCA1 mutation 26 68 58 64
BRCA2 mutation 3 8 6 7
BRCA1 and 2 mutation 0 0 1 1
Non-informative DNA test result 9 24 25 28
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ldiameter of 8mm was seen at microscopy. The histology of
patients 4 and 5 revealed a grade two papillary serous ovarian
adenocarcinoma and p53 staining was positive in both cases. The
tubes were all normal. They received no further treatment and are
alive without recurrence.
The mean follow-up of the 38 women who underwent bilateral
oophorectomy was 45 months (range 24.1–93.1 months). Three
cases of papillary serous peritoneal cancer were diagnosed 27, 33
and 70 months after prophylactic oophorectomy in 26 BRCA1
carriers (3.4 in 100 BRCA1 women-years). At prophylactic surgery,
a right-sided salpingo-oophorectomy was performed in patient 6,
since the left tube could not be recognised due to adhesions as a
result of culdotomic sterilisation. Due to a rising CA-125 27
months later, she underwent an exploratory laparatomy and was
found to have peritoneal papillary serous carcinoma. The tumour
cells were p53 positive. The left fallopian tube could not be
identified. The debulking was suboptimal. Despite a complete
remission after six paclitaxel/cisplatin cycles, she had a recurrence
22 months later. In the other two patients, only the ovaries had
been removed at prophylactic surgery. The tubes were left in situ
and the pathology reports showed no evidence of ovarian cancer.
Patient 7 had also a rising CA-125 33 months after the prophylactic
surgery. She had a debulking. The pathologist saw no fragments of
tumour intraluminal in the remnant tubes. P53 staining was
negative. Despite a complete remission after six paclitaxel/cisplatin
cycles, she died of liver metastases 53 months after the diagnosis.
Patient 8 had a distended abdomen due to ascites 70 months after
the oophorectomy. Serum CA-125 was also elevated. She also had a
debulking, where only the left tube could be identified. The tube
showed an intact architecture microscopically. The serous
papillary tumour cells were p53 positive. There is still no evidence
of disease 20 months after completion of six cycles of paclitaxel/
carboplatin.
No cases of papillary serous peritoneal cancer were registered in
the follow-up after the group with a bilateral salpingo-oophor-
ectomy including 58 BRCA carriers (0 in 60 women-years).
However, the mean follow-up of all these women was still short
(12 months, range 0.5–65.5).
DISCUSSION
In our series, five occult tumours were found in 58 BRCA1
germline mutation carriers (8.6%), who had undergone prophy-
lactic salpingo-oophorectomy (Table 2). None of the tumours were
suspected before or at the time of surgery; all five carcinomas were
only seen at microscopy. No occult tumours were found in the
remaining women (one BRCA1 and BRCA2, six BRCA2 and 25
A
B
E
F D
G
H
I
J
C G
Figure 1 Endometrioid adenocarcinoma (case patient 1), obliterating the lumen of the fallopian tube with a diameter of 2.5mm (haematoxylin (H&E)),
magnification  50). (B) Negative P53 staining of the same tumour in (A) (magnification  200). (C) Microscopic serous papillary adenocarcinoma (case
patient 2), 1.0cm in diameter (H&E, magnification  100). (D) Overexpression of P53 of the same tumour in (C) (magnification  200). (E) Poorly
differentiated adenocarcinoma (case patient 3), 5mm in diameter (H&E, magnification  25). (F) Positive P53 staining of the same tumour in (E)
(magnification  200). (G) Invasive serous papillary adenocarcinoma (case patient 4), with a diameter of 8mm. Note the formation of complex papillae
(H&E, magnification  100). (H) The same tumour as (H), P53 positive (magnification  200). (I) Serous papillary adenocarcinoma (case patient 5) with
mitotic activity (H&E, magnification  100). (J) The same tumour as (I), P53 positive (magnification  200).
Table 2 Clinical data of patients with occult carcinoma at salpingo-oophorectomy (patients 1–5) and PPSC (patients 6–8) after oophorectomy
Patients diagnosed at
prophylactic surgery BRCA status
Age
(year) Diagnosis (stage) Histology P53 staining Status
Follow-up
(months)
1 3875del4(BRCA1) 33 Fall tube (stage 1a) Endometrioid adenoca gr II Negative NED 46
2 BRCA1* 49 Fall tube (stage 3b) Serous papillary adenoca gr II Positive Rec. 20
3 2312del5(BRCA1) 45 Fall tube/ovary (stage 4) Adenoca gr III Positive Rec. 11
4 1411insT(BRCA1) 47 Ovary (stage 1c) Serous papillary adenoca gr II Positive NED 35
5 Exon11stop(BRCA1) 37 Ovary (stage 1a) Serous papillary adenoca gr II Positive NED 11
Patients diagnosed in
follow-up
BRCA status Age
(year)
Diagnosis (stage) Histology P53 staining Status Follow-up
(months)
6 Exon22del(BRCA1) 60 PPSC (stage 3c) Serous papillary adenoca gr I Positive Rec. 22
7 BRCA1* 53 PPSC (stage 3c) Adenoca gr III Negative DOD 53
8 BRCA1* 64 PPSC (stage 3c) Serous papillary adenoca gr III Positive NED 20
gr¼grade; Fall¼Fallopian; adenoca¼adenocarcinoma; NED¼no evidence of disease; Rec¼recurrence; PPSC¼peritoneal papillary serous carcinoma; DOD¼dead of
disease; *Not further specified.
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lwomen with non-informative test results, respectively) who
underwent a bilateral salpingo-oophorectomy, nor in the group
of 38 women (26 BRCA1, three BRCA2, nine women with non-
informative test results), who received a bilateral oophorectomy.
PPSC during follow-up was found in the BRCA1 carriers who
underwent an oophorectomy (3.4 per 100 women-years), and none
in the other groups.
Occult carcinomas have been reported before. Colgan et al
found five occult carcinomas of the ovaries and/or in situ or
invasive carcinoma of the fallopian tube among 60 patients (mean
age 48.5 years), all BRCA1 mutation positive. The prevalence of
occult tumours found in their series at prophylactic surgery in 27
BRCA1 mutation carriers is 18.5%. In the study of Lu et al, four
(12%) of 33 women (mean age 46 years) with a high calculated risk
of carrying a BRCA1 or BRCA2 mutation, who had undergone
prophylactic salpingo-oophorectomy, had occult ovarian cancer
found only at pathological examination (Lu et al, 2000). Three
women had a BRCA1 mutation, while one patient carried a BRCA2
mutation. Recently, Kauff et al described three cases (3.0%) of
unexpected findings at total abdominal hysterectomy/bilateral
salpingo-oophorectomy in 101 BRCA1 or BRCA2 germline
mutation carriers (mean age 47.5 years). One fallopian tube
carcinoma and two ovarian carcinomas were diagnosed. A
prevalence of 2.3% occult ovarian tumours was found by Rebbeck
et al in their series of 259 mutation carriers (mean age 42.0 years)
undergoing oophorectomy or salpingo-oophorectomy. Thus, a
prevalence of 2.3–18.5% of occult tumours in BRCA1 or BRCA2
germline mutation carriers has been found. First, this wide range is
probably attributable to the variable sizes of cohorts. Second, our
finding of 8.6% prevalence of occult tumours is established in
BRCA1 mutation carriers undergoing prophylactic salpingo-
oophorectomy, while other series did not make a clear distinction
between a salpingo-oophorectomy or an oophorectomy, nor
between BRCA1 and BRCA2 carriers. Third, the risk of developing
ovarian or fallopian tube carcinoma increases with age; so the low
prevalence found by Rebbeck et al might be due to a lower mean
age at prophylactic surgery. These studies show the importance of
attentiveness of occult tumours. It is interesting to see that no
occult carcinomas were found in our remaining group of women
with either a BRCA2 mutation or non-informative DNA test
results. Our results suggest that carriers of a BRCA1 germline
mutation have a substantial higher risk of occult carcinomas
compared to BRCA2 carriers or non-informative test results.
However, the power for the group of BRCA2 mutation carriers is
still low.
To estimate the prevalence of occult fallopian tube and ovarian
carcinoma at prophylactic salpingo-oophorectomy, we need to be
able to distinguish both carcinomas, which is often not possible in
advanced disease. In our series, two clear cases of fallopian tube
carcinoma and one fallopian tube/ovarian carcinoma were found.
In patient 3, the exact origin was not clear: the bulk of the tumour
was seen on the surface of the ovaries and both tubes. The
histological subtype ‘poorly differentiated adenocarcinoma’ was
also not helpful, since this cell type is associated with both tumours
(Scully et al, 2003).
Zweemer et al (2000) showed a loss of the wild-type BRCA1
allele in two fallopian tube carcinomas. In both patients, the
presence of a BRCA1 mutation was confirmed and a loss of the
wild-type BRCA1 allele in both tumours was shown. In our first
patient, we used the same method and also found a LOH of the
nonmutated BRCA1 allele in the fallopian tube tissue. These
findings strongly suggest that fallopian tube cancer is linked to
BRCA1 mutations.
Paley et al (2001) described two patients with occult fallopian
tube carcinomas at surgical prophylaxis, one carcinoma in situ
without extension to the stroma and the other patient with a
papillary serous adenocarcinoma without extension to the serosa.
It was advised that hysterectomy should be discussed with patients
who are considering prophylactic salpingo-oophorectomy. How-
ever, there are no long-term data to support hysterectomy in
addition to bilateral salpingo-oophorectomy. Until now, just a few
reports were published linking BRCA1 and 2 mutations with
uterine serous papillary carcinomas (Hornreich et al, 1999; Lavie
et al, 2000). Furthermore, hysterectomy has additional risks and
complications (Dicker et al, 1982). Given the anatomy, a
hysterectomy cannot prevent the development of PPSC. Piver
et al (1993) described nine cases of PPSC after abdominal total
hysterectomy and salpingo-oophorectomy.
All five occult carcinomas were discovered only at microscopical
examination. Neither transvaginal examination nor serum CA-125
determination was sufficient enough to detect these malignancies.
The combination of CA-125 and TVU was tested before in the
general population (Jacobs et al, 1999; Menon et al, 1999) and was
shown to be a feasible screenings method. However, failure to
detect more than 57% of early-stage disease is cited as the major
limitation of this type of screening (Jacobs et al, 1993). More
studies are required to establish in a large group of high-risk
patients the sensitivity, specificity and predictive value of ovarian
cancer screening, by means of pelvis examination, transvaginal
ultrasound and serum CA-125 determination. This high failure rate
of ovarian screening stresses the importance of complete enclosure
of both ovaries and tubes following prophylactic surgery in order
not to miss the presence of an occult carcinoma. We agree with
Colgan et al (2001) who advised to entirely section both tubes and
ovaries.
Four of the five occult tumours and two papillary serous
peritoneal carcinomas of women with a BRCA1 germline mutation
were positive of P53 protein. These findings are consistent with the
results of Lakhani et al, who found that breast carcinomas in
patients with a BRCA1 mutation are more likely to be positive for
p53 protein than controls.
Among the 38 patients who underwent a bilateral oophorectomy
were 26 BRCA1 mutation carriers, three of whom (3.4 in 100
women-years) developed papillary serous carcinoma of the
peritoneum 27, 33 and 70 months after the prophylactic surgery.
The lack of PPSC incidence in the salpingo-oophorectomy group
including 58 BRCA1 carriers (0 in 60 in women-years) could well
be explained by the difference in follow-up duration (45 months vs
12 months in the salpingo-oophorectomy group, respectively).
Only 10 women of the group with a salpingo-oophorectomy passed
the time point at which the first PPSC case occurred in the group
of women with a bilateral oophorectomy. For a meaningful
comparison between the two types of surgery, a longer follow-up is
needed. Another explanation of the difference of PPSC incidence
may be that PPSC could be a metastasis of the remnant fallopian
tubes. However, at the time of the diagnosis of PPSC no malignant
lesions were found in the fallopian tubes. Furthermore, it has been
shown that PPSC has developed after salpingo-oophorectomy
(Piver et al, 1993). So, we have concluded that PPSC is a primary
tumour and not a metastasis. Kauff et al reported one case of PPSC
(0.5 in 100 women-years) in 98 BRCA1 and BRCA2 mutation
carriers, who chose risk-reducing salpingo-oophorectomy with a
mean follow-up duration of 23.4 months. The incidence of PPSC in
our study (3.4 in 100 BRCA1 women-years) was higher than the 0.5
in 100 women-years, but this may be due to a longer mean follow-
up duration (45 months in our study vs 23.4 months in the study
by Kauff et al). Second, the later study also includes 42 BRCA2
carriers (43%), while the incidence in our series is established for
BRCA1 carriers who have a higher intrinsic ovarian cancer risk,
and this may also be true for PPSC. Other studies neither described
procedures nor whether the cases were BRCA1 or BRCA2 mutation
carriers (Piver et al, 1993; Rebbeck et al, 2002). Our series of 64
BRCA1 and BRCA2 mutation carriers after salpingo-oophorect-
omy includes only six BRCA2 carriers (9.4%). The only report of
PPSC occurring in two BRCA2 carriers after hysterectomy and
salpingo-oophorectomy is published recently (Foulkes et al, 2003).
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lUnfortunately, no data on follow-up of a cohort are given. Six
BRCA2 mutation carriers are found in 22 cases of PPSC by Levine
et al (2003), but whether these cases developed after a prophylactic
procedure is not mentioned. Clearly, it is too early to conclude that
BRCA2 carriers face a lower risk than BRCA1 carriers of
developing PPSC.
These results contribute to the thesis that BRCA1 germline
mutation carriers are not only at risk for ovarian cancer but also
for fallopian tube carcinoma and peritoneal papillary serous
carcinoma. Prophylactic salpingo-oophorectomy and sectioning
both tubes and ovaries is recommended in order to not miss any
occult carcinomas. Our data suggest that PPSC risk among BRCA2
carriers is lower than among BRCA1 carriers.
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